We are live on ! Find out more

MannKind Corp

MNKD

Market cap $1.23B

3.82 USD

+0.02

0.53%

At close Updated Oct 5, 4:00 PM EDT

Pre-market

After hours

3.82

0.00

0%

1 day

0.53%

5 days

14.03%

1 month

-8.17%

3 months

-10.54%

6 months

49.22%

Year to date

-31.79%

1 year

-32.51%

5 years

-19.24%

10 years

21.66%

About: MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

Employees: 592

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 34.6%

Neutral 50%

Negative 15.4%

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase 1b data for MNKD-201 in idiopathic pulmonary fibrosis, or IPF.

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

MannKind Corporation (NASDAQ:MNKD) shares are trading lower on Wednesday as traders react to the company's entry into a licensing and collaboration deal tied to an inhaled, rapid-acting GLP-1 program.

Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

MannKind to Present at Upcoming Investor Conferences

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind to Present at Upcoming Investor Conferences

Zacks Investment Research

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

MannKind: New Approvals Majorly Increase MannKind's Prospects

Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years.

MannKind: New Approvals Majorly Increase MannKind's Prospects

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

MannKind Q2 Earnings Call Highlights

MannKind NASDAQ: MNKD reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs.

MannKind Q2 Earnings Call Highlights

Zacks Investment Research

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

Zacks Investment Research

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind (MNKD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago.

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

See News Rankings

Price charts implemented using Lightweight Charts™